8-K: Sagimet Partner Ascletis Reports Positive Long-Term Acne Trial Data

Sagimet Biosciences announced positive 52-week long-term safety and efficacy data from its license partner Ascletis's Phase 3 clinical trial of denifanstat for moderate to severe acne in China.

Summary

• Ascletis Pharma Inc. announced positive topline results from its open-label Phase 3 clinical trial (ASC40-304) evaluating the long-term safety of ASC40 (denifanstat) tablets in patients with moderate to severe acne.
• Denifanstat was generally well tolerated over 52 weeks of exposure, with dry eye syndrome (5.5%) and dry skin (5.2%) being the only treatment-emergent adverse events (TEAEs) with an incidence rate of 5% or more.
• All denifanstat-related AEs were mild or moderate, with no Grade 3 or 4 AEs, no AE-related permanent discontinuations, and no denifanstat-related serious adverse events (SAEs).
• Subjects treated with denifanstat showed improvements in all efficacy endpoints (IGA score decrease, IGA score reduction from 3 to 0/1, percentage reduction in total and inflammatory skin lesion count) beyond those observed at 12 weeks.
• Ascletis previously announced in June 2025 that denifanstat met all primary, key secondary, and secondary endpoints in a 12-week randomized, double-blind, placebo-controlled Phase 3 trial (ASC40-303) for moderate to severe acne vulgaris.
• Ascletis's New Drug Application (NDA) for denifanstat for moderate to severe acne was accepted by China NMPA in December 2025.
• Sagimet's lead molecule, denifanstat, is also being developed for MASH, having met all primary endpoints in its Phase 2b FASCINATE-2 clinical trial.
• A Phase 1 PK clinical trial of a combination of denifanstat and resmetirom for MASH cirrhosis (F4) was completed in December 2025, with a Phase 2 trial planned for 2H 2026.
• Sagimet's second oral FASN inhibitor, TVB-3567, is in a Phase 1 first-in-human clinical trial for acne, initiated in June 2025.
• Sagimet had $125.5 million cash on hand as of September 30, 2025, expected to fund current operations for 2 years.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive update, driven by successful long-term clinical data for denifanstat in acne and significant regulatory progress in China, alongside continued advancement of its MASH and second-generation acne programs.

Positives

• Positive 52-week long-term safety and efficacy data for denifanstat (ASC40) in moderate to severe acne from Ascletis's open-label Phase 3 trial.
• Denifanstat was generally well tolerated with mild to moderate adverse events and no serious adverse events related to the drug.
• Efficacy endpoints showed improvements beyond 12 weeks of treatment.
• Ascletis's NDA for denifanstat in acne was accepted by China NMPA in December 2025, indicating significant regulatory progress.
• Denifanstat previously met all primary and secondary endpoints in a 12-week placebo-controlled Phase 3 trial for acne.
• Completion of Phase 1 PK clinical trial for denifanstat and resmetirom combination for MASH cirrhosis (F4) with no safety signals.
• Strong cash position of $125.5 million as of September 30, 2025, providing a 2-year runway.
• Denifanstat has FDA Breakthrough Therapy designation for MASH.
• Pre-clinical data demonstrated synergistic effect of combination of FASN inhibitor and resmetirom for MASH.

Negatives

• Hair thinning was reported in 18.8% of denifanstat-treated subjects in the MASH FASCINATE-2 trial, leading to discontinuation in 7% of patients, though it stabilized and reversed with dose adjustment.
• Dry eye syndrome (5.5%) and dry skin (5.2%) were noted as common TEAEs in the acne trial.

Risks

• The clinical development and therapeutic potential of denifanstat, TVB-3567, or any other drug candidates or combination therapies developed by Sagimet may not be realized.
• Sagimet's ability to advance drug candidates into and successfully complete clinical trials within anticipated timelines is uncertain.
• Topline clinical trial data may not be predictive of, and may differ from, final clinical data and later-stage clinical trials.
• Unfavorable new clinical trial data may emerge in other clinical trials of product candidates.
• Clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities.
• The success of Ascletis's development efforts for denifanstat is not guaranteed.
• The accuracy of Sagimet's estimates regarding its capital requirements.
• Sagimet's ability to maintain and successfully enforce adequate intellectual property protection.
• New risk factors and uncertainties may emerge from time to time, and management cannot predict all of them.

Future Outlook

Sagimet plans to initiate a Phase 2 clinical combination trial with denifanstat and resmetirom in patients with MASH cirrhosis (F4) in the second half of 2026, subject to regulatory consultation. The company also plans to consult with regulatory authorities regarding the Phase 2 trial design for TVB-3567 in moderate to severe acne, with a goal of initiating the trial in 2026. Data from Ascletis's Phase 3 acne trial may potentially be used for denifanstat development in acne outside China.

Management Comments

• "The topline results from Ascletis Phase 3 open-label acne trial in China build additional confidence in the clinical potential of FASN inhibition in acne." David Happel, CEO of Sagimet.
• "These results demonstrate FASN inhibitions potential as a novel mechanism of action for the treatment of acne." David Happel, CEO of Sagimet.
• "For moderate to severe acne patients, who are currently underserved by older agents, the potential of a new therapeutic option would be a welcome addition to the current treatment armamentarium." Dr. Neal Bhatia, Director of Clinical Dermatology at Therapeutics Clinical Research in San Diego and former Vice President of the American Academy of Dermatology.

Industry Context

StockSavvy.ai notes that the positive long-term safety and efficacy data for denifanstat in acne, coupled with the NDA acceptance in China, positions FASN inhibition as a promising novel mechanism of action in a large and underserved dermatology market. The continued development of denifanstat for MASH, particularly in combination with resmetirom for advanced fibrosis (F4), addresses a significant unmet need in metabolic disease, aligning with the industry's shift towards combination therapies for complex conditions. The initiation of TVB-3567's Phase 1 trial further diversifies Sagimet's FASN inhibitor pipeline.

Comparison to Industry Standards

• Denifanstat's safety profile in the 52-week acne trial, with dry eye syndrome (5.5%) and dry skin (5.2%) as the only TEAEs above 5%, appears favorable compared to some existing acne treatments which can have more severe or frequent side effects.
• The hair thinning incidence of 7-10% for GLP-1s is mentioned as a comparison point for denifanstat's hair thinning AE (18.8% in MASH trial, 7% discontinuation rate).
• The successful outcome of denifanstat's Phase 2b MASH trial, meeting both primary endpoints with significant fibrosis reduction, positions it competitively against other MASH drug candidates, especially given its FDA Breakthrough Therapy designation.
• The planned combination therapy with resmetirom, the first FDA-approved drug for non-cirrhotic MASH, aims to address the high unmet need in MASH cirrhosis (F4) patients, a segment where no approved treatments currently exist.

Stakeholder Impact

• Shareholders: Positive clinical trial results and regulatory progress could increase investor confidence and potentially lead to share price appreciation. The strong cash position provides financial stability.
• Patients (Acne): The potential for a new, effective, and well-tolerated oral therapeutic option for moderate to severe acne could significantly improve treatment outcomes and quality of life.
• Patients (MASH): The advancement of denifanstat and its combination with resmetirom, especially for MASH cirrhosis (F4), offers hope for patients with a high unmet medical need.
• Ascletis Pharma Inc.: As a license partner, Ascletis benefits from the positive trial results and NDA acceptance, strengthening its position in the China acne market.

Next Steps

• Data from Ascletis's Phase 3 open-label acne trial are planned to be shared in upcoming congresses and publications.
• Sagimet plans to develop a combination of denifanstat and resmetirom for patients with MASH cirrhosis (F4).
• A Phase 2 clinical combination trial with denifanstat and resmetirom in patients with MASH cirrhosis (F4) is planned to initiate in 2H 2026, subject to consultation with regulatory authorities.
• Sagimet plans to consult with regulatory authorities regarding the Phase 2 trial design for TVB-3567 in moderate to severe acne, with a goal of initiating the trial in 2026.
• Sagimet consulted with US FDA at the end of 2025 on the potential use of Ascletis Phase 3 data for the development of denifanstat in acne (e.g., as one of two registrational trials).
• Continue the development of tripalmitin and additional markers as potential biomarker(s) of treatment response for denifanstat.
• Identify FASN-dependent tumor types for potential FASN inhibitor development in oncology.

Key Dates

Recommendation

The filing presents highly positive clinical trial results for denifanstat in acne, demonstrating long-term safety and efficacy, which is further bolstered by the New Drug Application acceptance in China. This significantly de-risks a key pipeline asset and validates the FASN inhibition mechanism. Additionally, the successful completion of the Phase 1 PK trial for the MASH combination therapy and the strong cash runway provide a clear path for future development in another high-value indication. These developments suggest strong potential for future growth and market penetration.

Keywords

Sagimet Biosciences, SGMT, Ascletis Pharma, denifanstat, ASC40, FASN inhibitor, acne, Phase 3 clinical trial, MASH, NASH, TVB-3567, biopharmaceutical, clinical-stage, drug development, dermatology, metabolic disease, fibrosis, resmetirom, combination therapy, NDA, China NMPA, investor presentation